Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist.

Hims & Hers Health has sparred with Novo Nordisk for months over the Danish drugmaker’s refusal to sell weight-loss drugs on its platform, but the bitter feud appears to have reached its end. Hims shares were rallying Monday after Novo said it had agreed to sell its Ozempic and Wegovy injectables, as well as an oral version of Wegovy, through Hims’ online pharmacy. Hims surged 38% to $21.75, putting the stock on track for its largest single-day percentage increase on record, according to Dow Jones Market Data.